247 related articles for article (PubMed ID: 32011965)
41. A comparison of treatment patterns, healthcare resource utilization, and costs among young adult Medicaid beneficiaries with schizophrenia treated with paliperidone palmitate or oral atypical antipsychotics in the US.
Manjelievskaia J; Amos TB; El Khoury AC; Vlahiotis A; Cole A; Juneau P
J Med Econ; 2018 Dec; 21(12):1221-1229. PubMed ID: 30238806
[TBL] [Abstract][Full Text] [Related]
42. Real-world healthcare resource utilization and costs in patients with chronic lymphocytic leukemia: differences between patients treated with first-line ibrutinib or bendamustine + rituximab.
Irwin D; Wilson K; Thompson S; Choudhry A
Curr Med Res Opin; 2021 Apr; 37(4):623-628. PubMed ID: 33563073
[TBL] [Abstract][Full Text] [Related]
43. Association of teriparatide adherence and persistence with clinical and economic outcomes in Medicare Part D recipients: a retrospective cohort study.
Hazel-Fernandez L; Louder AM; Foster SA; Uribe CL; Burge RT
BMC Musculoskelet Disord; 2013 Jan; 14():4. PubMed ID: 23281846
[TBL] [Abstract][Full Text] [Related]
44. One-Year Outcomes of an Integrated Multiple Sclerosis Disease Management Program.
Groeneweg M; Forrester SH; Arnold B; Palazzo L; Zhu W; Yoon P; Scearce T
J Manag Care Spec Pharm; 2018 May; 24(5):458-463. PubMed ID: 29694287
[TBL] [Abstract][Full Text] [Related]
45. Treatment Initiation Patterns, Modifications, and Medication Adherence Among Newly Diagnosed Heart Failure Patients: A Retrospective Claims Database Analysis.
Deschaseaux C; McSharry M; Hudson E; Agrawal R; Turner SJ
J Manag Care Spec Pharm; 2016 May; 22(5):561-71. PubMed ID: 27123917
[TBL] [Abstract][Full Text] [Related]
46. Comparison of Time to Next Treatment, Health Care Resource Utilization, and Costs in Patients with Chronic Lymphocytic Leukemia Initiated on Front-line Ibrutinib or Chemoimmunotherapy.
Emond B; Sundaram M; Romdhani H; Lefebvre P; Wang S; Mato A
Clin Lymphoma Myeloma Leuk; 2019 Dec; 19(12):763-775.e2. PubMed ID: 31678080
[TBL] [Abstract][Full Text] [Related]
47. Treatment Patterns and Medication Use in Patients with Postherpetic Neuralgia.
Gudin J; Fudin J; Wang E; Haylon T; Patel K; Goss TF
J Manag Care Spec Pharm; 2019 Dec; 25(12):1387-1396. PubMed ID: 31589557
[TBL] [Abstract][Full Text] [Related]
48. Treatment Patterns, Healthcare Resource Utilization, and Costs of Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma in the US.
Yang X; Zanardo E; Lejeune D; De Nigris E; Sarpong E; Farooqui M; Laliberté F
Oncologist; 2024 Mar; 29(3):e360-e371. PubMed ID: 38280190
[TBL] [Abstract][Full Text] [Related]
49. Improvement in Parameters of Hematologic and Immunologic Function and Patient Well-being in the Phase III RESONATE Study of Ibrutinib Versus Ofatumumab in Patients With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma.
Barrientos JC; O'Brien S; Brown JR; Kay NE; Reddy NM; Coutre S; Tam C; Mulligan S; Jaeger U; Devereux S; Pocock C; Robak T; Schuster SJ; Schuh A; Gill D; Bloor A; Dearden C; Moreno C; Cull G; Hamblin M; Jones JA; Eckert K; Solman IG; Suzuki S; Hsu E; James DF; Byrd JC; Hillmen P
Clin Lymphoma Myeloma Leuk; 2018 Dec; 18(12):803-813.e7. PubMed ID: 30249389
[TBL] [Abstract][Full Text] [Related]
50. Atypical antipsychotic adherence is associated with lower inpatient utilization and cost in bipolar I disorder.
Broder MS; Greene M; Chang E; Hartry A; Yan T; Yermilov I
J Med Econ; 2019 Jan; 22(1):63-70. PubMed ID: 30376745
[TBL] [Abstract][Full Text] [Related]
51. Adherence, Persistence, and Health Care Costs for Patients Receiving Dipeptidyl Peptidase-4 Inhibitors.
Rascati KL; Worley K; Meah Y; Everhart D
J Manag Care Spec Pharm; 2017 Mar; 23(3):299-306. PubMed ID: 28230454
[TBL] [Abstract][Full Text] [Related]
52. Overall survival, adverse events, and economic burden in patients with chronic lymphocytic leukemia receiving systemic therapy: Real-world evidence from the medicare population.
Goyal RK; Nagar SP; Kabadi SM; Le H; Davis KL; Kaye JA
Cancer Med; 2021 Apr; 10(8):2690-2702. PubMed ID: 33734606
[TBL] [Abstract][Full Text] [Related]
53. Medication Adherence, Health Care Utilization, and Costs in Patients With Major Depressive Disorder Initiating Adjunctive Atypical Antipsychotic Treatment.
Broder MS; Greene M; Yan T; Chang E; Hartry A; Yermilov I
Clin Ther; 2019 Feb; 41(2):221-232. PubMed ID: 30616973
[TBL] [Abstract][Full Text] [Related]
54. Retrospective database analysis of the impact of prior authorization for type 2 diabetes medications on health care costs in a Medicare Advantage Prescription Drug Plan population.
Bergeson JG; Worley K; Louder A; Ward M; Graham J
J Manag Care Pharm; 2013 Jun; 19(5):374-84. PubMed ID: 23697475
[TBL] [Abstract][Full Text] [Related]
55. Cost of Disease Progression in Patients with Chronic Lymphocytic Leukemia, Acute Myeloid Leukemia, and Non-Hodgkin's Lymphoma.
Reyes C; Engel-Nitz NM; DaCosta Byfield S; Ravelo A; Ogale S; Bancroft T; Anderson A; Chen M; Matasar M
Oncologist; 2019 Sep; 24(9):1219-1228. PubMed ID: 30808814
[TBL] [Abstract][Full Text] [Related]
56. Real-World Adherence and Persistence to Oral Disease-Modifying Therapies in Multiple Sclerosis Patients Over 1 Year.
Johnson KM; Zhou H; Lin F; Ko JJ; Herrera V
J Manag Care Spec Pharm; 2017 Aug; 23(8):844-852. PubMed ID: 28737986
[TBL] [Abstract][Full Text] [Related]
57. Predictors of adherence to oral anticancer medications: An analysis of 2010-2018 US nationwide claims.
Vyas A; Descoteaux A; Kogut S; Parikh MA; Campbell PJ; Green A; Westrich K
J Manag Care Spec Pharm; 2022 Aug; 28(8):831-844. PubMed ID: 35876294
[No Abstract] [Full Text] [Related]
58. Associations of Renin-Angiotensin System Antagonist Medication Adherence and Economic Outcomes Among Commercially Insured US Adults: A Retrospective Cohort Study.
Campbell PJ; Axon DR; Taylor AM; Pickering M; Black H; Warholak T; Chinthammit C
J Am Heart Assoc; 2020 Sep; 9(17):e016094. PubMed ID: 32844732
[TBL] [Abstract][Full Text] [Related]
59. Real-world persistence and costs among patients with chronic migraine treated with onabotulinumtoxinA or calcitonin gene-related peptide monoclonal antibodies.
Schwedt TJ; Lee J; Knievel K; McVige J; Wang W; Wu Z; Gillard P; Shah D; Blumenfeld AM
J Manag Care Spec Pharm; 2023 Oct; 29(10):1119-1128. PubMed ID: 37776119
[No Abstract] [Full Text] [Related]
60. Real-world treatment sequencing and healthcare costs among CLL/SLL patients treated with venetoclax.
Rogers KA; Emond B; Manceur AM; Kinkead F; Lafeuille MH; Lefebvre P; Huang Q
Curr Med Res Opin; 2021 Aug; 37(8):1409-1420. PubMed ID: 34003049
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]